Overall, emerging evidence suggests that TREM2 acts as a key regulatory hub linking innate immune receptor signaling with cytokine-mediated inflammatory pathways, thereby maintaining microglial homeostasis and modulating neuroinflammatory and synaptic outcomes in PD, ALS, and other neurodegenerative diseases (Yeh et al., 2017). The gene discussed is TREM2; the disease is amyotrophic lateral sclerosis.